View Item 

Show simple item record

Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity‐matched National Cancer Database analysis
dc.contributor.authorKamarajah, Sivesh K.
dc.contributor.authorBednar, Filip
dc.contributor.authorCho, Clifford S.
dc.contributor.authorNathan, Hari
dc.date.accessioned2021-05-12T17:22:17Z
dc.date.available2022-05-12 13:22:16en
dc.date.available2021-05-12T17:22:17Z
dc.date.issued2021-04-15
dc.identifier.citationKamarajah, Sivesh K.; Bednar, Filip; Cho, Clifford S.; Nathan, Hari (2021). "Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity‐matched National Cancer Database analysis." Cancer (8): 1266-1274.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/167433
dc.publisherWiley Periodicals, Inc.
dc.subject.otherdistal cholangiocarcinoma
dc.subject.otherchemotherapy
dc.subject.otherradiotherapy
dc.subject.otherresection
dc.subject.othersurvival
dc.titleSurvival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity‐matched National Cancer Database analysis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167433/1/cncr33356_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167433/2/cncr33356.pdf
dc.identifier.doi10.1002/cncr.33356
dc.identifier.sourceCancer
dc.identifier.citedreferenceBenson AB, D’Angelica MI, Abbott DE, et al. Guidelines insights: hepatobiliary cancers, version 2.2019. J Natl Compr Canc Netw. 2019; 17: 302 ‐ 310. doi: 10.6004/jnccn.2019.0019
dc.identifier.citedreferenceVersteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020; 38: 1763 ‐ 1773. doi: 10.1200/JCO.19.02274
dc.identifier.citedreferenceVern‐Gross TZ, Shivnani AT, Chen K, et al. Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2011; 81: 189 ‐ 198. doi: 10.1016/j.ijrobp.2010.05.001
dc.identifier.citedreferenceEcker BL, Vining CC, Roses RE, et al. Identification of patients for adjuvant therapy after resection of carcinoma of the extrahepatic bile ducts: a propensity score‐matched analysis. Ann Surg Oncol. 2017; 24: 3926 ‐ 3933. doi: 10.1245/s10434‐017‐6095‐9
dc.identifier.citedreferenceHughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys. 2007; 68: 178 ‐ 182. doi: 10.1016/j.ijrobp.2006.11.048
dc.identifier.citedreferenceNelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2009; 73: 148 ‐ 153. doi: 10.1016/j.ijrobp.2008.07.008
dc.identifier.citedreferenceTakada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002; 95: 1685 ‐ 1695. doi: 10.1002/cncr.10831
dc.identifier.citedreferenceEbata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018; 105: 192 ‐ 202. doi: 10.1002/bjs.10776
dc.identifier.citedreferenceMorak MJM, van der Gaast A, Incrocci L, et al. Adjuvant intra‐arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer. Ann Surg. 2008; 248: 1031 ‐ 1041. doi: 10.1097/sla.0b013e318190c53e
dc.identifier.citedreferenceNeoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC‐3 periampullary cancer randomized trial. JAMA. 2012; 308: 147 ‐ 156. doi: 10.1001/jama.2012.7352
dc.identifier.citedreferenceSmeenk HG, van Eijck CH, Hop WC, et al. Long‐term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long‐term results of EORTC trial 40891. Ann Surg. 2007; 246: 734 ‐ 740. doi: 10.1097/SLA.0b013e318156eef3
dc.identifier.citedreferenceRangarajan K, Simmons G, Manas D, Malik H, Hamady ZZ. Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: a systematic review and meta‐analysis. Eur J Surg Oncol. 2020; 46 ( 4 pt A ): 684 ‐ 693. doi: 10.1016/j.ejso.2019.11.499
dc.identifier.citedreferenceBilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007; 110: 738 ‐ 744. doi: 10.1002/cncr.22852
dc.identifier.citedreferenceMerkow RP, Rademaker AW, Bilimoria KY. Practical guide to surgical data sets: National Cancer Database (NCDB). JAMA Surg. 2018; 153: 850 ‐ 851. doi: 10.1001/jamasurg.2018.0492
dc.identifier.citedreferenceGiobbie‐Hurder A, Gelber RD, Regan MM. Challenges of guarantee‐time bias. J Clin Oncol. 2013; 31: 2963 ‐ 2969. doi: 10.1200/JCO.2013.49.5283
dc.identifier.citedreferenceAustin PC. The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014; 33: 1242 ‐ 1258. doi: 10.1002/sim.5984
dc.identifier.citedreferenceBen‐Josef E, Guthrie KA, El‐Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015; 33: 2617 ‐ 2622. doi: 10.1200/JCO.2014.60.2219
dc.identifier.citedreferenceWoo SM, Ryu JK, Lee SH, et al. Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol. 2007; 14: 3195 ‐ 3201. doi: 10.1245/s10434‐007‐9537‐y
dc.identifier.citedreferenceCourtin‐Tanguy L, Rayar M, Bergeat D, et al. The true prognosis of resected distal cholangiocarcinoma. J Surg Oncol. 2016; 113: 575 ‐ 580. doi: 10.1002/jso.24165
dc.identifier.citedreferenceKomaya K, Ebata T, Shirai K, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017; 104: 426 ‐ 433. doi: 10.1002/bjs.10452
dc.identifier.citedreferenceKurosaki I, Hatakeyama K, Minagawa M, Sato D. Portal vein resection in surgery for cancer of biliary tract and pancreas: special reference to the relationship between the surgical outcome and site of primary tumor. J Gastrointest Surg. 2008; 12: 907 ‐ 918. doi: 10.1007/s11605‐007‐0387‐5
dc.identifier.citedreferenceKim BH, Kim K, Chie EK, et al. Long‐term outcome of distal cholangiocarcinoma after pancreaticoduodenectomy followed by adjuvant chemoradiotherapy: a 15‐year experience in a single institution. Cancer Res Treat. 2017; 49: 473 ‐ 483. doi: 10.4143/crt.2016.166
dc.identifier.citedreferenceMaeta T, Ebata T, Hayashi E, et al. Pancreatoduodenectomy with portal vein resection for distal cholangiocarcinoma. Br J Surg. 2017; 104: 1549 ‐ 1557. doi: 10.1002/bjs.10596
dc.identifier.citedreferenceMoekotte AL, Lof S, Van Roessel S, et al. Histopathologic predictors of survival and recurrence in resected ampullary adenocarcinoma: international multicenter cohort study. Ann Surg. 2020; 272: 1086 ‐ 1093. doi: 10.1097/SLA.0000000000003177
dc.identifier.citedreferenceNeoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350: 1200 ‐ 1210. doi: 10.1056/NEnglJMed.oa032295
dc.identifier.citedreferenceHorgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta‐analysis. J Clin Oncol. 2012; 30: 1934 ‐ 1940. doi: 10.1200/JCO.2011.40.5381
dc.identifier.citedreferenceGhidini M, Tomasello G, Botticelli A, et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta‐analysis. HPB (Oxford). 2017; 19: 741 ‐ 748. doi: 10.1016/j.hpb.2017.05.010
dc.identifier.citedreferenceAndrianello S, Paiella S, Allegrini V, et al. Pancreaticoduodenectomy for distal cholangiocarcinoma: surgical results, prognostic factors, and long‐term follow‐up. Langenbecks Arch Surg. 2015; 400: 623 ‐ 628. doi: 10.1007/s00423‐015‐1320‐0
dc.identifier.citedreferenceKoo TR, Eom KY, Kim IA, et al. Patterns of failure and prognostic factors in resected extrahepatic bile duct cancer: implication for adjuvant radiotherapy. Radiat Oncol J. 2014; 32: 63 ‐ 69. doi: 10.3857/roj.2014.32.2.63
dc.identifier.citedreferencevan der Gaag NA, Kloek JJ, de Bakker JK, et al. Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinoma. Ann Oncol. 2012; 23: 2642 ‐ 2649. doi: 10.1093/annonc/mds077
dc.identifier.citedreferenceKim HJ, Kim CY, Hur YH, et al. Prognostic factors for survival after curative resection of distal cholangiocarcinoma: perineural invasion and lymphovascular invasion. Surg Today. 2014; 44: 1879 ‐ 1886. doi: 10.1007/s00595‐014‐0846‐z
dc.identifier.citedreferenceKiriyama M, Ebata T, Aoba T, et al. Prognostic impact of lymph node metastasis in distal cholangiocarcinoma. Br J Surg. 2015; 102: 399 ‐ 406. doi: 10.1002/bjs.9752
dc.identifier.citedreferenceKamarajah SK, Burns WR, Frankel TL, Cho CS, Nathan H. Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: a surveillance, epidemiology and end results (SEER) analysis. Ann Surg Oncol. 2017; 24: 2023 ‐ 2030. doi: 10.1245/s10434‐017‐5810‐x
dc.identifier.citedreferenceJang JY, Kim SW, Park DJ, et al. Actual long‐term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg. 2005; 241: 77 ‐ 84. doi: 10.1097/01.sla.0000150166.94732.88
dc.identifier.citedreferenceYamamoto M, Takasaki K, Otsubo T, Katsuragawa H, Katagiri S. Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2001; 8: 154 ‐ 157. doi: 10.1007/s005340170039
dc.identifier.citedreferencePrimrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019; 20: 663 ‐ 673. doi: 10.1016/S1470‐2045(18)30915‐X
dc.identifier.citedreferenceKlinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5‐fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999; 230: 776 ‐ 782; discussion 782‐784.
dc.identifier.citedreferenceKamarajah SK, Sonnenday CJ, Cho CS, et al. Association of adjuvant radiotherapy with survival after margin‐negative resection of pancreatic ductal adenocarcinoma: a propensity‐matched National Cancer Database (NCDB) analysis. Ann Surg. 2019. doi: 10.1097/SLA.0000000000003242. Online ahead of print.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr33356_am.pdf
Size:
405.5KB
Format:
PDF
View/Open
Name:
cncr33356.pdf
Size:
211.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.